This episode reviews articles from the May/June 2019 issue of AllergyWatch:
- Secondhand Exposure to Vaping: A Problem for Kids with Asthma
- All That Sneezes May End Up With Wheezes
- Predictors of Enhanced Response to Benralizumab
- Understanding AERD….Some Progress, But Is It Enough?
- Does Your Patient Have Immune Deficiency? It Could Depend on Which Lab You Ask!
- NFKB1 Is the Most Common Monogenic Cause of CVID in Europe
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
- Dr. Lee was on an advisory board for Teva.
- Dr. Kuruvilla has received consulting fees from AstraZeneca.
- Dr. Fineman – Speaker: AstraZeneca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
ACAAI presents this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to the procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that may be referenced.